Literature DB >> 3353441

Protection by opioids against gastric lesions caused by necrotizing agents.

S Ferri1, E Speroni, S Candeletti, E Cavicchini, P Romualdi, P Govoni, M Marchini.   

Abstract

The synthetic opioid met-enkephalin analog [D-Ala2, MePhe4, Met(0)5ol] enkephalin (DAMME) and the opiate morphine injected intraperitoneally to rats at doses of 0.5-2 and 5-20 mg/kg, respectively, showed a protective effect on gastric damage induced by oral administration of necrotizing agents (0.6 N HCl or 0.2 N NaOH solutions, 1 ml/rat). The protection was prevented by naltrexone (10 mg/kg s.c.), an opioid antagonist with long-lasting activity. Histological sections of mucosal samples from animals pretreated with morphine (10 mg/kg i.p.) and DAMME (1 mg/kg i.p.) showed less alteration of the columnar epithelium, with a normal glandular structure, than untreated rats. A mediation of prostaglandins is suggested, since indomethacin (10 mg/kg s.c.) significantly reduced the protective effects of opioids.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3353441     DOI: 10.1159/000138371

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  4 in total

1.  Preservation of retina ganglion cell function by morphine in a chronic ocular-hypertensive rat model.

Authors:  Shahid Husain; Yasir Abdul; Craig E Crosson
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-06-28       Impact factor: 4.799

2.  Delta-opioid agonist SNC-121 protects retinal ganglion cell function in a chronic ocular hypertensive rat model.

Authors:  Yasir Abdul; Naseem Akhter; Shahid Husain
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-03-11       Impact factor: 4.799

3.  Mechanism of intragastric nicotine protection against ethanol-induced gastric injury.

Authors:  K Endoh; M Baker; F W Leung
Journal:  Dig Dis Sci       Date:  1991-01       Impact factor: 3.199

4.  Neuroinflammatory reactions in experimental gastric ulcer: target for mucosal protection.

Authors:  K Gyires
Journal:  Inflammopharmacology       Date:  1997       Impact factor: 4.473

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.